OCT 29, 2014 01:30 PM PDT
PDX Tumor Models for Oncology Research and Preclinical Prediction
Presented at the Cancer: Research, Discovery and Therapeutics Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
50 52 2310

Speakers:
  • Business Unit Management, Senior Business Unit Manager, The Jackson Laboratory
    Biography
      Dr. Walter Ausserer leads the In Vivo Pharmacology Services business unit at The Jackson Laboratory, which specializes in mouse models engrafted with human tissues. Over the past two decades, he has held senior positions at leading bioanalytical technology companies, including ProteinSimple, ForteBio, and Caliper Life Sciences. Dr. Ausserer holds a Ph.D. in Chemistry from Cornell University and received postdoctoral training in Cancer Biology in the laboratory of Robert Sutherland at SRI International.

    Abstract:
    Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson Laboratory, we have established a repository of more than 350 well-characterized PDX tumor models and are working with leading cancer centers on translational studies at the forefront of personalized medicine. This presentation will explore recent progress toward the use of PDX and humanized mouse models for predictive oncology treatment.

    Show Resources
    Loading Comments...